Secarna Pharmaceuticals and Vect-Horus Collaborate on RNA Therapeutics for CNS Disorders

Secarna Pharmaceuticals GmbH & Co. KG and Vect-Horus have announced a strategic research collaboration. This partnership combines Secarna's OligoCreator® technology and Vect-Horus' VECTrans® platform to enhance systemic delivery of RNA-targeted therapies for central nervous system (CNS) disorders by crossing the blood-brain barrier.

Secarna, based in Martinsried, Germany, and Vect-Horus, located in Marseille, France, aim to address challenges in the targeted delivery of therapeutics. The collaboration aspires to develop treatments for neurodegenerative and other CNS illnesses, leveraging Secarna's expertise in RNA therapeutics and Vect-Horus' proficiency in advanced delivery systems.

The combined technologies hope to offer new approaches for treating CNS diseases, improving patient outcomes through targeted treatments. This partnership represents a strategic step for both companies in expanding their capabilities in CNS indications.